The SGLT2 inhibitors reduce the renal threshold for glucose excretion from approximately 10 mmol/L (180 mg/dL) to approximately 2.2 mmol/L (40 mg/dL) and the resulting glycosuria can exceed 100 g in DM patients and 50–60 g in individuals with normal glucose metabolism, effects attenuated in patients with an eGFR < 50 mL/min/1.73 m2 and minimal when the eGFR < 30 mL/min/1.73 m2 [54,55]. This evidence concerns the gene SLC5A2 and diabetes mellitus.